Hemostatic disorders in type 1 diabetes mellitus

Seminars in Thrombosis and Hemostasis

Volumn 37, Issue 1, 2011, Pages 58-65

  Targher, Giovanni ^a   Chonchol, Michel ^b   Zoppini, Giacomo ^a   Franchini, Massimo ^c  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

coagulation; fibrinolysis; hemostatic disorders; Type 1 diabetes

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; ADVANCED GLYCATION END PRODUCT; BETA THROMBOGLOBULIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD40 LIGAND; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBRINOPEPTIDE A; HEMOGLOBIN A1C; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; PADGEM PROTEIN; PROTEIN C; PROTEIN S; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOCYTE FACTOR 4; THROMBOXANE A2; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; YKL 40 PROTEIN;

ALBUMINURIA; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; CARDIOVASCULAR DISEASE; CONTINUOUS INFUSION; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL MICROPARTICLE; FIBRINOLYSIS; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HEMOSTASIS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN TREATMENT; MICROALBUMINURIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THROMBOCYTE ADHESIVENESS; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE DYSFUNCTION;

ADULT; BLOOD COAGULATION; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; FIBRINOLYSIS; HEMOSTATIC DISORDERS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 79251476868     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0030-1270072     Document Type: Article

References (42)

1. American Diabetes Association. Standards of medical care in diabetes2010. Diabetes Care 2010 33 (Suppl 1) S11-S61
2. Eckel R H., Wassef M, Chait A et al. Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group II: pathogenesis of atherosclerosis in diabetes. Circulation 2002 105 18 e138-e143
3. Franchini M, Targher G, Montagnana M, Lippi G. The metabolic syndrome and the risk of arterial and venous thrombosis. Thromb Res 2008 122 6 727-735
4. Mina A, Favaloro E J., Koutts J. Hemostatic dysfunction associated with endocrine disorders as a major risk factor and cause of human morbidity and mortality: a comprehensive meta-review. Semin Thromb Hemost 2007 33 8 798-809
5. Targher G, Chonchol M, Miele L, Zoppini G, Pichiri I, Muggeo M. Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome. Semin Thromb Hemost 2009 35 3 277-287
6. Blann A D., Lip G Y. Endothelial integrity, soluble adhesion molecules and platelet markers in type 1 diabetes mellitus. Diabet Med 1998 15 8 634-642
7. el Khawand C, Jamart J, Donckier J et al. Hemostasis variables in type I diabetic patients without demonstrable vascular complications. Diabetes Care 1993 16 8 1137-1145
8. Yngen M, Ostenson C G., Hu H, Li N, Hjemdahl P, Walln N H. Enhanced P-selectin expression and increased soluble CD40 Ligand in patients with type 1 diabetes mellitus and microangiopathy: evidence for platelet hyperactivity and chronic inflammation. Diabetologia 2004 47 3 537-540
9. Devaraj S, Glaser N, Griffen S, Wang-Polagruto J, Miguelino E, Jialal I. Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes. Diabetes 2006 55 3 774-779
10. Dav G, Chiarelli F, Santilli F et al. Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration. Circulation 2003 107 25 3199-3203
11. Hu H, Li N, Yngen M, Ostenson C G., Walln N H., Hjemdahl P. Enhanced leukocyte-platelet cross-talk in type 1 diabetes mellitus: relationship to microangiopathy. J Thromb Haemost 2004 2 1 58-64
12. Haitas B, Barnes A J., Cederholm-Williams S A., Moore J, Shogry M E., Turner R C. Abnormal endothelial release of fibrinolytic activity and fibronectin in diabetic microangiopathy. Diabetologia 1984 27 5 493-496
13. Carmassi F, Morale M, Puccetti R et al. Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus. Thromb Res 1992 67 6 643-654
14. Reverter J L., Reverter J C., Tssies D et al. Thrombomodulin and induced tissue factor expression on monocytes as markers of diabetic microangiopathy: a prospective study on hemostasis and lipoproteins in insulin-dependent diabetes mellitus. Am J Hematol 1997 56 2 93-99
15. Fasching P, Veitl M, Rohac M et al. Elevated concentrations of circulating adhesion molecules and their association with microvascular complications in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1996 81 12 4313-4317
16. Targher G, Bertolini L, Zoppini G, Zenari L, Falezza G. Increased plasma markers of inflammation and endothelial dysfunction and their association with microvascular complications in type 1 diabetic patients without clinically manifest macroangiopathy. Diabet Med 2005 22 8 999-1004
17. Smulders R A., Stehouwer C D., Schalkwijk C G., Donker A J., van Hinsbergh V W., TeKoppele J M. Distinct associations of HbA1c and the urinary excretion of pentosidine, an advanced glycosylation end-product, with markers of endothelial function in insulin-dependent diabetes mellitus. Thromb Haemost 1998 80 1 52-57
18. Giusti C, Schiaffini R, Brufani C, Pantaleo A, Vingolo E M., Gargiulo P. Coagulation pathways and diabetic retinopathy: abnormal modulation in a selected group of insulin dependent diabetic patients. Br J Ophthalmol 2000 84 6 591-595
19. Elhadd T A., Kennedy G, Hill A et al. Abnormal markers of endothelial cell activation and oxidative stress in children, adolescents and young adults with type 1 diabetes with no clinical vascular disease. Diabetes Metab Res Rev 1999 15 6 405-411
20. Zoppini G, Targher G, Cacciatori V, Guerriero A, Muggeo M. Chronic cigarette smoking is associated with increased plasma circulating intercellular adhesion molecule 1 levels in young type 1 diabetic patients. Diabetes Care 1999 22 11 1871-1874
21. Schalkwijk C G., Poland D C., van Dijk W et al. Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia 1999 42 3 351-357
22. Rathcke C N., Persson F, Tarnow L, Rossing P, Vestergaard H. YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with type 1 diabetes and increases with levels of albuminuria. Diabetes Care 2009 32 2 323-328
23. Romano M, Pomilio M, Vigneri S et al. Endothelial perturbation in children and adolescents with type 1 diabetes: association with markers of the inflammatory reaction. Diabetes Care 2001 24 9 1674-1678
24. Antovic J P., Yngen M, Ostenson C G. et al. Thrombin activatable fibrinolysis inhibitor and hemostatic changes in patients with type I diabetes mellitus with and without microvascular complications. Blood Coagul Fibrinolysis 2003 14 6 551-556
25. Harmanci A, Kandemir N, Dagdelen S et al. Thrombin-activatable fibrinolysis inhibitor activity and global fibrinolytic capacity in type 1 diabetes: evidence for normal fibrinolytic state. J Diabetes Complications 2006 20 1 40-44
26. Leurs P B., van Oerle R, Hamulyak K, Wolffenbuttel B H. Tissue factor pathway inhibitor activity in patients with IDDM. Diabetes 1995 44 1 80-84
27. Iorio A, Federici M O., Mourvaki E et al. Impaired endothelial antithrombotic activity following short-term interruption of continuous subcutaneous insulin infusion in type 1 diabetic patients. Thromb Haemost 2007 98 3 635-641
28. Rigla M, Mateo J, Fontcuberta J, Souto J C., de Leiva A, Prez A. Normalisation of tissue factor pathway inhibitor activity after glycaemic control optimisation in type 1 diabetic patients. Thromb Haemost 2000 84 2 223-227
29. Franklin V L., Khan F, Kennedy G, Belch J J., Greene S A. Intensive insulin therapy improves endothelial function and microvascular reactivity in young people with type 1 diabetes. Diabetologia 2008 51 2 353-360
30. Schnbeck U, Libby P. CD40 signaling and plaque instability. Circ Res 2001 89 12 1092-1103
31. Harding S A., Sommerfield A J., Sarma J et al. Increased CD40 ligand and platelet-monocyte aggregates in patients with type 1 diabetes mellitus. Atherosclerosis 2004 176 2 321-325
32. Varo N, Vicent D, Libby P et al. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones. Circulation 2003 107 21 2664-2669
33. Targher G, Zoppini G. Soluble CD40L in young type 1 diabetic individuals without clinical microvascular and macrovascular complications. Diabetes Care 2004 27 5 1236-1237
34. Sabatier F, Darmon P, Hugel B et al. Type 1 and type 2 diabetic patients display different patterns of cellular microparticles. Diabetes 2002 51 9 2840-2845
35. Sibal L, Aldibbiat A, Agarwal S C. et al. Circulating endothelial progenitor cells, endothelial function, carotid intima-media thickness and circulating markers of endothelial dysfunction in people with type 1 diabetes without macrovascular disease or microalbuminuria. Diabetologia 2009 52 8 1464-1473
36. Goldberg R B. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab 2009 94 9 3171-3182
37. Costacou T, Lopes-Virella M F., Zgibor J C. et al, The Pittsburgh Epidemiology of Diabetes Complications Study. Markers of endothelial dysfunction in the prediction of coronary artery disease in type 1 diabetes. J Diabetes Complications 2005 19 4 183-193
38. Astrup A S., Tarnow L, Pietraszek L et al. Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10 years: association with mortality and decline of glomerular filtration rate. Diabetes Care 2008 31 6 1170-1176
39. Lin J, Glynn R J., Rifai N et al. Inflammation and progressive nephropathy in type 1 diabetes in the diabetes control and complications trial. Diabetes Care 2008 31 12 2338-2343
40. Lopes-Virella M F., Carter R E., Gilbert G E. et al, Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications Cohort Study Group. Risk factors related to inflammation and endothelial dysfunction in the DCCT/EDIC cohort and their relationship with nephropathy and macrovascular complications. Diabetes Care 2008 31 10 2006-2012
41. Soedamah-Muthu S S., Chaturvedi N, Pickup J C., Fuller J H., EURODIAB Prospective Complications Study Group The EURODIAB Prospective Complications Study (PCS). Relationship between plasma sialic acid and fibrinogen concentration and incident micro- and macrovascular complications in type 1 diabetes. Diabetologia 2008 51 3 493-501
42. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005 54 6 1615-1625